Search Results - "DEVOS, Timothy"

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study by Passamonti, Francesco, Prof, Griesshammer, Martin, Prof, Palandri, Francesca, MD, Egyed, Miklos, Prof, Benevolo, Giulia, MD, Devos, Timothy, Prof, Callum, Jeannie, FRCPC, Vannucchi, Alessandro M, Prof, Sivgin, Serdar, MD, Bensasson, Caroline, PhD, Khan, Mahmudul, PhD, Mounedji, Nadjat, MD, Saydam, Guray, Prof

“…Summary Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy at controlling…”
Get full text

CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis by Vermeersch, Gael, Proost, Paul, Struyf, Sofie, Gouwy, Mieke, Devos, Timothy

“…BCR::ABL1 negative myeloproliferative neoplasms (MPN) form a distinct group of hematologic malignancies characterized by sustained proliferation of cells from…”
Get full text

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial by Griesshammer, Martin, Saydam, Guray, Palandri, Francesca, Benevolo, Giulia, Egyed, Miklos, Callum, Jeannie, Devos, Timothy, Sivgin, Serdar, Guglielmelli, Paola, Bensasson, Caroline, Khan, Mahmudul, Ronco, Julian Perez, Passamonti, Francesco

“…RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the best available therapy (BAT) in…”
Get full text

Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel by Devos, Timothy, Meers, Stef, Boeckx, Nancy, Gothot, Andre, Deeren, Dries, Chatelain, Bernard, Chatelain, Christian, Devalet, Bérangère

“…Despite its considerable morbidity and mortality, paroxysmal nocturnal haemoglobinuria (PNH) is still underdiagnosed. Patients with PNH can suffer from…”
Get full text

Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management by Vermeersch, Gaël, Delforge, Michel, Havelange, Violaine, Graux, Carlos, Michaux, Lucienne, Devos, Timothy

“…Chronic neutrophilic leukemia (CNL) is a rare but potentially aggressive negative myeloproliferative neoplasm, characterized by sustained mature, neutrophilic…”
Get full text

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis by Devos, Timothy, Selleslag, Dominik, Granacher, Nikki, Havelange, Violaine, Benghiat, Fleur Samantha

“…Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem…”
Get full text

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib by Mesa, Ruben, Verstovsek, Srdan, Platzbecker, Uwe, Gupta, Vikas, Lavie, David, Giraldo, Pilar, Recher, Christian, Kiladjian, Jean-Jacques, Oh, Stephen T, Gerds, Aaron T, Devos, Timothy, Passamonti, Francesco, Vannucchi, Alessandro M, Egyed, Miklos, Lech-Maranda, Ewa, Pluta, Andrzej, Nilsson, Lars, Shimoda, Kazuya, McLornan, Donal, Kawashima, Jun, Klencke, Barbara, Huang, Mei, Strouse, Bryan, Harrison, Claire

Get full text

Characterization of the Human Blood Virome in Iranian Multiple Transfused Patients by Thijssen, Marijn, Khamisipour, Gholamreza, Maleki, Mohammad, Devos, Timothy, Li, Guangdi, Van Ranst, Marc, Matthijnssens, Jelle, Pourkarim, Mahmoud Reza

“…Blood transfusion safety is an essential element of public health. Current blood screening strategies rely on targeted techniques that could miss unknown or…”
Get full text

The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer by Wijgaerts, Anouck, Wittevrongel, Christine, Thys, Chantal, Devos, Timothy, Peerlinck, Kathelijne, Tijssen, Marloes R, Van Geet, Chris, Freson, Kathleen

“…Gray platelet syndrome is named after the gray appearance of platelets due to the absence of α-granules. It is caused by recessive mutations in , resulting in…”
Get full text

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene by van der Krogt, Jo-Anne, Bempt, Marlies Vanden, Ferreiro, Julio Finalet, Mentens, Nicole, Jacobs, Kris, Pluys, Ursula, Doms, Kathleen, Geerdens, Ellen, Uyttebroeck, Anne, Pierre, Pascal, Michaux, Lucienne, Devos, Timothy, Vandenberghe, Peter, Tousseyn, Thomas, Cools, Jan, Wlodarska, Iwona

“…Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is characterized by 2p23/ aberrations, including the classic t(2;5)(p23;q35)/…”
Get full text

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project by Mora, Barbara, Giorgino, Toni, Guglielmelli, Paola, Rumi, Elisa, Maffioli, Margherita, Rambaldi, Alessandro, Caramella, Marianna, Komrokji, Rami, Gotlib, Jason, Kiladjian, Jean Jacques, Cervantes, Francisco, Devos, Timothy, Palandri, Francesca, De Stefano, Valerio, Ruggeri, Marco, Silver, Richard T, Benevolo, Giulia, Albano, Francesco, Cavalloni, Chiara, Barraco, Daniela, Merli, Michele, Pietra, Daniela, Casalone, Rosario, Barbui, Tiziano, Rotunno, Giada, Cazzola, Mario, Vannucchi, Alessandro Maria, Passamonti, Francesco

Get full text

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations by Al Assaf, Carla, Van Obbergh, Florence, Billiet, Johan, Lierman, Els, Devos, Timothy, Graux, Carlos, Hervent, Anne-Sophie, Emmerechts, Jan, Tousseyn, Thomas, De Paepe, Pascale, Papadopoulos, Petros, Michaux, Lucienne, Vandenberghe, Peter

“…The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia…”
Get full text

Germline heterozygous SH2B3-mutations and (idiopathic) erythrocytosis: Detection of a previously undescribed mutation by Vermeersch, Gaël, Devos, Timothy, Devos, Helena, Lambert, Frédéric, Poppe, Bruce, Van Hecke, Sam

“…Erythrocytosis or polycythemia refers to a true or apparent increase in hemoglobin or hematocrit. When no etiology of erythrocytosis is identified, people are…”
Get full text

Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review by Houthuys, Jona F., Wilmer, Alexander P., Peetermans, Marijke, Meersseman, Philippe, Devos, Timothy

“…Discontinuation of Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, can induce symptom-relapse and even life-threatening adverse events. Due to increasing use of RUX,…”
Get full text

Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases by Thijssen, Marijn, Devos, Timothy, Ejtahed, Hanieh-Sadat, Amini-Bavil-Olyaee, Samad, Pourfathollah, Ali Akbar, Pourkarim, Mahmoud Reza

“…In the lack of an effective vaccine and antiviral treatment, convalescent plasma (CP) has been a promising therapeutic approach in past pandemics. Accumulating…”
Get full text

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial by Devos, Timothy, Geukens, Tatjana, Schauwvlieghe, Alexander, Ariën, Kevin K, Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N, Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, Meyfroidt, Geert

“…The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of…”
Get full text

Levenseindezorg beter aanpakken by Devos, Timothy, Haekens, An

“…Geen samenvatting…”
Get full text

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis by Oh, Stephen T., Verstovsek, Srdan, Gupta, Vikas, Platzbecker, Uwe, Devos, Timothy, Kiladjian, Jean‐Jacques, McLornan, Donal P., Perkins, Andrew, Fox, Maria Laura, McMullin, Mary Frances, Mead, Adam J., Egyed, Miklos, Mayer, Jiri, Sacha, Tomasz, Kawashima, Jun, Huang, Mei, Strouse, Bryan, Mesa, Ruben

“…Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association…”
Get full text

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study by Schrezenmeier, Hubert, Kulasekararaj, Austin, Mitchell, Lindsay, Sicre de Fontbrune, Flore, Devos, Timothy, Okamoto, Shinichiro, Wells, Richard, Rottinghaus, Scott T., Liu, Peng, Ortiz, Stephan, Lee, Jong Wook, Socié, Gérard

“…Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority…”
Get full text

S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED‐INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON‐134 TRIAL by Van Dijck, Ruben, VAN DER Holt, Ron, Meijer, Ellen, Devos, Timothy, Hazenberg, Mette, Van Der Poel, Marjolein, Breems, Dimitri, Deleu, Lien, Schaap, Nicolaas, Te Boekhorst, Peter André Willem

Get full text